Megan

[Colorectal Cancer Alliance @CCAlliance]

What's the latest on molecular profiling & immunotherapy advances in colorectal cancer? Drs Heinz-Josef Lenz, Cathy Eng (@cathengMD), & Sara Lonardi (@sara_lonardi1) presented at #ASCO25. Watch the on-demand version from @PeerView now 👉 https://t.co/1h5A0MAaSj

[Jen Silverman @SpeakJen]

🎯Better data. Better decisions. Better outcomes.

Join @PeerView + @ZEROCancer at #GU26 for a case-based discussion on personalizing #prostatecancer care from early to advanced disease.

💬 Drs. Fizazi | @SFreedlandMD | Smith
🗓️ 2/26 | 6:45 PM PST
👉 https://t.co/poZCkFCe6x

[Jen Silverman @SpeakJen]

The RCC playbook is changing — are you?
🚨 #Oncology & #KidneyCancer clinicians — don’t miss this! 🚨

Turn today’s data into real-world #RCC care with @PeerView + @KidneyCancer at #GU26.

💬 @montypal | @PBarataMD | @crisuarez08
🗓️ 2/26 | ⏰ 7 PM PST | 🔗https://t.co/vLy0DSqhxM

[Jen Silverman @SpeakJen]

🚨 #RSV vaccine rates are too low. We can do better‼️

✅ Show up
✅ Speak up
✅ Change outcomes

Join @PeerView at #APhA2026 on 3/28 with Drs. Abdul-Mutakabbir (@JayCDoesID) & Dang (@USCMann) for practical strategies to improve RSV vaccine uptake.
🔗 https://t.co/in7twkbgCz

[Athena Tsimikas, MD @athenatsimikas]

I’m looking forward to speaking alongside Drs. Mathieu and Bajaj at an upcoming @PeerView Live symposium during #ATTD2026. Join us as we discuss practical ways to optimize basal insulin use in #Type2Diabetes. Attend in Barcelona or virtually on March 13: https://t.co/80PnwZtwvW

[Jen Silverman @SpeakJen]

Managing #CRSwNP in the biologics era? 🧬Personalizing care starts here!

Join @PeerView on Sat, 3/21 | 12 PM during #ENT for the PA-C for expert insights on personalizing care for T2i-driven disease.
💬 Drs. Luong, Codispoti & Carly Luethy, PA-C
👉 https://t.co/urHWRcxWzM
#CME

[Jacinda Abdul-Mutakabbir (Dr.JAM) PharmD MPH FIDSA @JayCdoesID]

Can't wait for this program!

[Jen Silverman @SpeakJen]

#PAR isn’t “just allergies.” 🌬️ It’s chronic, underestimated, and evolving.
✨ IL-13 biologics are changing what’s possible.
🎤 Join @PeerView at #AAAAI25 featuring Drs. Ellen Sher, @CFaaoa, & Steven Weinstein
📅 Sat, Feb 28 | 6:30 PM EST
👉 https://t.co/nW1rGj1UPm #Allergy

[Pedro C Barata, MD MSc FACP @PBarataMD]

Want to stay ahead in #RCC care? Join me, @montypal, and @crisuarez08 live San Fran or online 2/26 at 7:00 PM PST for Unlocking the Potential of Modern RCC Therapies. Discover practical strategies to tailor tx & improve outcomes:
https://t.co/x2bjESluVq @PeerView @KidneyCancer

[CLL Society Inc. @CllSociety]

Pathways to Personalized Remission in #CLL: Get expert guidance on managing R/R CLL, including insights on sequential use of non-covalent BTKis and immunotherapy options. Join us 12/05 at 7:30 AM EST at #ASH25.

https://t.co/slND2zDBss

#MedEd #Hematology #CancerCare
@PeerView

[HealthTree Foundation @HealthTree]

Newly diagnosed with #MantleCellLymphoma - Join Drs. Dreyling, Maddocks, and Ryan on 12/5 at 7:30 AM
EST for a session on BTKi options and clinical decision-making. Learn what this means for patients and
families. Produced with @PeerView https://t.co/Ldo2LAS7T7
#ASH25 #HemOnc

[HealthTree Foundation @HealthTree]

Join Guillermo Garcia-Manero, MD (@garciamanero), María Díez Campelo, MD, PhD (@madicamp), and
Sangeetha Venugopal, MD (@drsangeetmd) on 12/5 at 7:30 AM EST for an #MDS #MedEd event with
@PeerView at #ASH25.👉 https://t.co/raLlAbgeaf

[HealthTree Foundation @HealthTree]

Join Drs. David Sallman, Tapan Kadia & Emma Searle (@dremmasearle) on 12/5 at 7:30 AM EST during
#ASH25 for an #AML #MedEd event produced with @PeerView. https://t.co/1RUsgtVRzS
#HemOnc #PrecisionMedicine

[HealthTree Foundation @HealthTree]

Many Roads to #Myeloma Remission: Learn the latest evidence on the sequential use of BCMA and non-
BCMA immunotherapy options for relapsed/refractory #MultipleMyeloma. Join us 12/5 at 7:30 AM EST.
Produced with @PeerView
https://t.co/OykTQjYCb2
#ASH25 #Hematology #Oncology #MedEd

[HealthTree Foundation @HealthTree]

Join Prof. Dr. Max S. Topp, MD, @samehgaballa MD, and Dr. @DeepJagMD MPH, on 12/5 at AM EST during #ASH25 for a #NonHodgkinLymphoma #MedEd event. This is a great opportunity to learn about the latest in lymphoma treatments. Register here: https://t.co/jaqgzTl49d @PeerView
#HemOnc #Hematology #Oncology

[PeerView @PeerView]

Consider this your official invite 🎉

Join PeerView Live’s in-person & virtual hematology symposia during #ASH25 on 12/5 at 7 AM EST. Learn, discuss, and connect with top experts in the field! @cvdelucaPVI #MedEd #Oncology #Hematology

Register for one of our 8 programs at the ASH annual meeting: https://t.co/EEWS5xeCK7

[PeerView @PeerView]

Hear from Dr. David Sallman about what’s coming during #ASH25 with PeerView Live. Don’t miss our in-person & virtual symposia, 7AM EST on 12/5! #AML #Hematology #Oncology #MedEd

🔗 https://t.co/fN6yV7QI6Z

[María Díez Campelo @madicamp]

Join me, @garciamanero and @drsangeetmd for a @PeerView live session at #ASH25, highlighting the latest advances in #MDS care—including diagnostics, new therapies, and individualized treatment strategies.
📅 12/5 | 7 AM EST | Hyatt Regency Orlando

[PeerView @PeerView]

@bensolomon1 @Todd_M_Bauer @LUNGevity ✅ How would you manage hypercholesterolemia in a 54-yo 👳‍♀️ with ALK+ mNSCLC experiencing a good response to 1L Lorlatinib?

@bensolomon1, @Todd_M_Bauer, @LUNGevity
#LCSM #TargetedTherapy

[PeerView @PeerView]

@bensolomon1 @Todd_M_Bauer @LUNGevity 👳‍♀️🫁 Case continues: After 12 weeks on lorlatinib, the patient has excellent response, but develops hypercholesterolemia. What would you do next?

Vote 📊 and comment 💬 with your rationale!

@bensolomon1, @Todd_M_Bauer, @LUNGevity
#LCSM #NSCLC